Matching articles for "Glucose monitoring devices"
Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System
The Medical Letter on Drugs and Therapeutics • November 21, 2016; (Issue 1508)
The FDA has approved the Minimed 670G (Medtronic),
a hybrid closed-loop insulin delivery system for use in
patients ≥14 years old with type 1 diabetes. The system
uses an algorithm to automatically adjust...
The FDA has approved the Minimed 670G (Medtronic),
a hybrid closed-loop insulin delivery system for use in
patients ≥14 years old with type 1 diabetes. The system
uses an algorithm to automatically adjust basal insulin
doses based on readings from a continuous glucose
monitor (CGM). It fully automates basal insulin
delivery in "auto" mode, but is considered a "hybrid"
system (not a true "artificial pancreas") because it
requires some action by the patient. The 670G system
is expected to become available in Spring 2017.
MiniMed 530G: An Insulin Pump with Low-Glucose Suspend Automation
The Medical Letter on Drugs and Therapeutics • December 9, 2013; (Issue 1431)
The FDA has approved the MiniMed 530G
(Medtronic), an insulin pump used in combination with
a continuous glucose monitoring sensor (Enlite) that
can stop delivery of insulin when interstitial...
The FDA has approved the MiniMed 530G
(Medtronic), an insulin pump used in combination with
a continuous glucose monitoring sensor (Enlite) that
can stop delivery of insulin when interstitial glucose
reaches a prespecified low level. It is the only sensoraugmented
insulin pump available in the US with this
capability.
Continuous Glucose Monitoring
The Medical Letter on Drugs and Therapeutics • May 2, 2011; (Issue 1363)
A variety of continuous glucose monitoring (CGM)
devices have been used in an effort to reduce the hypoglycemia
and wide glucose excursions that complicate
insulin treatment of diabetes. Since the last...
A variety of continuous glucose monitoring (CGM)
devices have been used in an effort to reduce the hypoglycemia
and wide glucose excursions that complicate
insulin treatment of diabetes. Since the last Medical
Letter issue reviewing such devices, some new devices
and some new data on old devices have become available.
The devices currently marketed in the US for personal
use are listed in Table 1.
Continuous Glucose Monitoring
The Medical Letter on Drugs and Therapeutics • February 12, 2007; (Issue 1254)
A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue...
A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
New Glucose-monitoring Technologies
The Medical Letter on Drugs and Therapeutics • December 8, 2003; (Issue 1171)
Improved glucose meters and 2 sensing systems for continuous monitoring have become available for management of...
Improved glucose meters and 2 sensing systems for continuous monitoring have become available for management of diabetes.
GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device
The Medical Letter on Drugs and Therapeutics • May 14, 2001; (Issue 1104)
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.